The structures of 16,17-dihydrorifamycin S and 16,17-dihydro-17-hydroxyrifamycin S, two novel ansamycins from the recombinant strain C 5/42 of Nocardia niediterranei, were elucidated by physico-chemical methods. In addition structure-activity relationships among 16,17-hydrogenated rifamycins are discussed.
In the course of our search for new ansamycins by mutation or recombination we found that a recombinant strain C 5/42 of Nocardia mediterranei produces the two hitherto unknown ansamycins 16,17-dihydrorifamycin S and 16,17-dihydro-17-hydroxyrifamycin S together with the already known 16,17-dehydrorifamycin G2), rifamycin W3) and rifamycin W-lactone2) (Fig. 1) *.
In the first part of this paper we report on the isolation and characterization of recombinant strain C 5/42 and on the fermentation, purification and structural elucidation of the two new rifamycins. In the second part we discuss some biological properties of the compounds from recombinant strain C 5/42 and of 16,17-dihydrorifampicin SV which is a derivative of 16,17-dihydrorifamycin S, together with the results of some transformation studies. The structures of the ansamycins from the C 5/42 strain provide useful information about structure-activity relationships among the rifamycins.
Isolation and Characterization of Recombinant Strain C 5/42
Strain C 5/42 was isolated as a recombinant strain from a cross between two Nocardia mediterranei mutants, T101 and F 1/24, which are blocked at different steps in rifamycin biosynthesis. Strain T 101 is blocked in the transformation of rifamycin SV to rifamycin B. It produces rifamycin SV and is auxotrophic for proline and resistant to streptomycin.
Strain F 1/24 is blocked in the transformation of protorifamycin I to rifamycin W and produces protorifamycin I. The two strains were crossed on agar slants using a method described in an earlier papers) and recombinant colonies were isolated on minimal agar6) containing 25 pg/ml streptomycin. By this means a selection was achieved which allowed only those recombinants to grow which had inherited the pro+ allele from strain F 1/24 and the str° allele from strain T 101. Out of 150 recombinant colonies isolated and checked for their stability by streaking out on the same selective medium, 105 with stable pro+ strR phenotype were selected. These were tested for rifamycin production by fermentation in liquid medium 1487)) in 200-ml Erlenmeyer flasks at 28°C. After 7 days incubation, 4 ml samples of culture broth from each strain were filtered, adjusted to pH 2 with HCl and extracted once with an equal volume of methylene chloride. The organic phases were concentrated 20 fold and analyzed by thin-layer chromatography (Merck silica gel 60 F_,; plates).
R. CRICCHIO et al. from the Gruppo Lepetit describe the same compound, isolated from a mutant of Nocardia mediterranei, in a later publication4).
VOL. XXXV NO. 5 THE JOURNAL OF ANTIBIOTICS
After developing with chloroform -methanol, 4: 1, new rifamycins could be distinguished from the rifamycins produced by the parental strains. Of the 105 recombinants tested, 67 produced rifamycin SV, 34 protorifamycin I and one strain with the number C 5/42 a mixture of new products and no rifamycin SV or protorifamycin I. The remaining 3 strains were found to produce a mixture of protorifamycin I, rifamycin SV and rifamycin B. It could be shown by further cultivation on selective plates that these 3 strains were not stable haploid recombinants but possessed unstable phenotypes which segregated into the two parental phenotypes.
Strain C 5/42 has inherited the pro+ gene from parent strain F 1/24 and the strn gene from parent strain T 101. The morphology of this recombinant strain is the same as that of the two parental strains.
It does not sporulate under our conditions and the mycelium breaks up into rod like fragments of 5 -20 pm length.
To obtain material for a preliminary characterization of the fermentation products, strain C 5/42
was fermented in shake flasks with medium 148 and the culture filtrate was extracted as described above.
Thin-layer chromatography using different solvent systems for development showed that C 5/42
produces rifamycin G as its main product and two new products, but no rifamycin SV or B, which are the normal endproducts or rifamycin fermentation. In the FD-mass spectrum the molecular ion M+ was found at m/z 713 (C37H47NO13) which is 16 mass units higher than found for 16,17-dihydrorifamycin S.
In the 13C NMR spectrum (Table 1) The H-17 proton of 16,17-dihydro-l7-hydroxyrifamycin S is now found at a lower field (3.7 ppm) as a properties with those of Rimactan. The compound was synthesized starting from 16,17-dihydrorifamycin S by the sequence of reactions (Scheme 1).
The 13C NMR and 1H NMR spectra of 16,17-dihydrorifampicin SV (Table 1) were in good agreement with the corresponding spectra of rifampicin SV. 
Biological Activity
The various 16,17-dihydrorifamycins have been tested for their in vitro activity against a variety of bacteria (Table 2) . Surprisingly the loss of the 16,17-double bond leads to a 100-300 fold lower activity against Gram-positive bacteria.
Rifamycin G1) also belongs to the 16,17-dihydrorifamycins and contains a p-pyrone ring instead of a quinone ring system. This compound has been reported to be totally inactive against bacteria."
In contrast the 16,17-dehydro derivative of rifamycin G2) has some antibacterial activity. This demonstrates the importance of the 16,17-double bond of the rifamycins for biological activity.
This fact is borne out even more clearly by measuring the inhibitory activity of the various derivatives on RNA polymerase, the target enzyme for the rifamycins8,9). As shown in Table 3 
Discussion
The isolation of recombinant strain C 5/42 is a further example of the biosynthetic potential of intraspecific recombination between N. mediterranei strains blocked in rifamycin biosynthesis (see Reference 5) . The recombinant strain produces mainly rifamycin G, which so far has only been detected as a sideproduct along with the rifamycin complex in a fermentation with a rifamycin B producing strain1). In addition C 5/42 produces 16,17-dihydrorifamycin S, and 16,17-dihydro-17-hydroxyrifamycin S, two hitherto unknown rifamycins, together with 16,17-dehydrorifamycin G which was first isolated from recombinant strain R-212).
In addition to rifamycin G1), 16,17-dihydrorifamycin S and 16,17-dihydro-17-hydroxyrifamycin S are two further examples in the rifamycin series where the a,B,r,5-diene system of the ansa-chain is partially hydrogenated.
As is shown by the biological activity as well as the activity against RNA polymerase of these two compounds and of 16,17-dihydrorifampicin SV, the presence of the 16,17-double bond is essential for full biological activity of the rifamycins.
16,17-Dihydro-17-hydroxyrifamycin S is another one of the numerous examples12~14) where hydroxylation in the ansa-chain has taken place, suggesting again that the hydroxylating enzymes do not act very specifically.
The transformation data together with an analysis of the structural differences of the new rifamycins allow two possible biogenetic pathways to be postulated for the synthesis of rifamycin G starting from rifamycin SV (Fig. 4) . VOL. XXXV NO. 5
